# Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

> **NCT02449538** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT02449538
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02449538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02449538, "Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02449538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*